Drug data last refreshed 2d ago
RISPERDAL (risperidone) is an atypical antipsychotic small molecule approved in 2003 for schizophrenia and related psychotic disorders. It works by antagonizing dopamine D2 and serotonin 5-HT2A receptors in the central nervous system. The drug is available in oral tablet and orally disintegrating formulations.
As a mature product approaching loss of exclusivity, the brand team is likely focused on managed decline and portfolio transition rather than growth initiatives.
Atypical Antipsychotic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection
Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants
Worked on RISPERDAL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moRISPERDAL positions are concentrated in established brand support, managed care advocacy, and medical affairs rather than new product development. Career growth opportunities are limited as the product transitions toward post-LOE management.